Tumor Necrosis Factor: How to Make a Killer Molecule Tumor-Specific?
Journal:
Current Cancer Drug Targets
Volume:
5
Page:
381-392
Author(s):
Rudolf Lucas, Matthias Kresse, Markus Latta and Albrecht Wendel
New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Journal:
Current Cancer Drug Targets
Volume:
5
Page:
393-419
Author(s):
Christian Hafner, Albrecht Reichle and Thomas Vogt
Purine Nucleoside Analogues for the Treatment of Hematological Malignancies: Pharmacology and Clinical Applications
Journal:
Current Cancer Drug Targets
Volume:
5
Page:
421-444
Author(s):
T. Robak, A. Korycka, M. Kasznicki, A. Wrzesien-Kus and P. Smolewski
Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies
Journal:
Current Cancer Drug Targets
Volume:
5
Page:
445-455
Author(s):
Daruka Mahadevan and Nikhil Shirahatti
P-Glycoprotein - Implications of Metabolism of Neoplastic Cells and Cancer Therapy
Journal:
Current Cancer Drug Targets
Volume:
5
Page:
457-468
Author(s):
Albert Breier, Miroslav Barancik, Zdenka Sulova and Branislav Uhrik
Ribozymes, DNAzymes and Small Interfering RNAs as Therapeutics
Journal:
Current Drug Targets
Volume:
6
Page:
647-653
Author(s):
M. Sioud and P. O. Iversen
Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Journal:
Current Drug Targets
Volume:
6
Page:
665-682
Author(s):
K. Fjeldstad and S. O. Kolset
Identification of New Targets for Therapy of Osteolytic Bone Disease in Multiple Myeloma
Journal:
Current Drug Targets
Volume:
6
Page:
701-711
Author(s):
O. Hjertner, T. Standal, M. Borset, A. Sundan and A. Waage
Strategies for Biology- and Molecular-Based Treatment of Myelodysplastic Syndromes
Journal:
Current Drug Targets
Volume:
6
Page:
713-725
Author(s):
E. H. Lindberg
Pharmacogenomics: Integration into Drug Discovery and Development
Journal:
Current Topics in Medicinal Chemistry
Volume:
5
Page:
1039-1046
Author(s):
Keith Johnson, John Thompson and Aidan Power